GPN Vaccines specializes in whole cell broad spectrum vaccines for both humans and animals.

Its current vaccine is a genetically engineered derivative of the non-encapsulated S. pneumoniae strain Rx1 inactivated with a sterilising dose of high-energy photons is able to elicit serotype-independent protection in experimental models of invasive pneumococcal disease.  This includes induction of a vigorous opsonophagocytic antibody (OPA) response in rabbits immunised with Gamma-PNTM.